The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 12 May 2009, www.theannals.com, DOI 10.1345/aph.1L167.
 The Annals of Pharmacotherapy: Vol. 43, No. 6, pp. 1107-1114. DOI 10.1345/aph.1L167
© 2009 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Google Scholar
Right arrow Articles by Sincak, C. A
Right arrow Articles by Schmidt, J. M
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sincak, C. A
Right arrow Articles by Schmidt, J. M

NEW DRUG DEVELOPMENTS

Iclaprim, a Novel Diaminopyrimidine for the Treatment of Resistant Gram-Positive Infections

Carrie A Sincak, PharmD BCPS

Associate Professor of Pharmacy Practice and Vice-Chair of Acute Care, College of Pharmacy, Midwestern University Chicago, Downers Grove, IL

Justin M Schmidt, PharmD BCPS

Assistant Professor of Pharmacy Practice, College of Pharmacy, Midwestern University Chicago

Reprints: Dr. Sincak, College of Pharmacy, Midwestern University Chicago, 555 31st St., Downers Grove, IL 60515, fax 630/515-6958, csinca{at}midwestern.edu

OBJECTIVE: To review the pharmacology, microbiology, in vitro susceptibility, pharmacokinetics, clinical trial data, safety, and tolerability of iclaprim, a novel dihydrofolate reductase (DHFR) inhibitor.

DATA SOURCES: A MEDLINE search was conducted from 1966 through December 2008. Additional sources included abstracts from meetings of the Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America from 2001 to 2008 and information available from the manufacturer's Web site.

STUDY SELECTION AND DATA EXTRACTION: In vitro and clinical studies, in addition to Phase 1, 2, and 3 clinical trials, were included.

DATA SYNTHESIS: Iclaprim, a novel diaminopyrimidine and DHFR antagonist, has a mechanism of action similar to that of trimethoprim. It has in vitro activity mainly against gram-positive organisms, including resistant Staphylococcus aureus. In Phase 2 and 3 clinical trials, oral and intravenous administration of iclaprim was effective and well tolerated for the treatment of complicated skin and skin structure infections (cSSSI). Trials are currently ongoing for the treatment of ventilator-associated and healthcare-associated pneumonia.

CONCLUSIONS: Iclaprim is a promising antimicrobial agent for the treatment of gram-positive organisms, including resistant S. aureus and trimethoprim-, macrolide-, fluoroquinolone-, and glycopeptide-resistant strains. Additionally, in vitro activity similar to that of trimethoprim has been observed against gram-negative and atypical organisms.

Key Words: AR-100, dihydrofolate reductase, gram-positive, iclaprim

Published Online, May 12, 2009. www.theannals.com, DOI 10.1345/aph.1L167

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-09-010-H01-P




homecopy help contact us subscription past issues search current issue
Copyright © 2009 by Harvey Whitney Books Company.